The finding that removal of TRLs from the circulation is a more important determinant of plasma TG than secretion of TRL is interesting, but it remains to be clarified whether the apoC-III-induced impaired clearance of VLDL particles in subjects with atherogenic dyslipidemia is predominantly due to reduced lipolytic capacity or to the impaired removal of TRL remnants by the liver. The gene discussed is APOC3; the disease is metabolic syndrome.